| PBM licensure required | Required by statute |
| Spread pricing banned (Medicaid) | Banned in Medicaid |
| Pharmacist gag clauses prohibited | Prohibited by statute |
| Copay accumulator banned | Permitted |
Maryland requires PBM licensure or registration before operating in the state, with renewal cycles, fee schedules, and disclosure requirements set by statute or rule. State licensure authority typically vests in the Maryland Board of Pharmacy or the Department of Insurance, depending on whether the PBM regulation is framed as pharmacy practice or insurance regulation. Following Rutledge v PCMA (2020), state PBM regulation that does not directly conflict with ERISA preemption is permissible, and most states have enacted or strengthened PBM oversight statutes in the post-Rutledge period.
Maryland Medicaid program has adopted a spread-pricing transparency or pass-through model for pharmacy claims processed through Medicaid Managed Care PBMs. Pass-through pricing requires PBMs to charge the Medicaid plan exactly what they reimburse to dispensing pharmacies (typically benchmarked to NADAC plus a dispensing fee), eliminating the historic "spread" margin where PBMs charged plans more than they paid pharmacies. Commercial market spread-pricing rules are typically narrower and require disclosure rather than outright prohibition. Verify the current Maryland Medicaid pharmacy benefit contract structure and any updated commercial-market rules with the Maryland Department of Insurance.
Maryland has enacted a Maximum Allowable Cost (MAC) appeal statute giving pharmacies a defined process to challenge PBM reimbursement at or below acquisition cost. Standard elements include: a defined appeal window (typically 7-30 days from claim adjudication), PBM duty to respond within a statutory timeframe, disclosure of MAC pricing source, and a process for retroactive correction when the appeal succeeds. The statute typically applies to generic drugs reimbursed at MAC and is enforced by the Maryland Board of Pharmacy or Department of Insurance, with civil penalties for non-compliance. Independent pharmacies are the primary beneficiaries of MAC appeal protections.
Pharmacist gag clauses (PBM contract provisions prohibiting pharmacists from informing patients of lower cash-pay or competitor prices) are prohibited under both federal law (Patient Right to Know Drug Prices Act, 2018, for Medicare; Know the Lowest Price Act, 2018, for commercial coverage) and parallel Maryland statutes that often extend additional protections. Pharmacists may disclose cash-pay or competitor pricing to patients without violating PBM network contracts. Verify any Maryland-specific additional protections (such as duty-to-disclose lower prices) with the Maryland Board of Pharmacy.
Maryland has not enacted a statutory copay accumulator prohibition. Health plans and PBMs operating in Maryland may use "copay accumulator" or "copay maximizer" programs that do not credit manufacturer copay assistance toward the patient's deductible or out-of-pocket maximum. Patients with high-deductible plans and manufacturer-card-dependent specialty medications face full deductible exposure once the manufacturer card is exhausted. Maryland patients affected by copay accumulators may pursue federal pathway through expanded patient-assistance foundations or 340B contract pharmacies where eligible. Verify current Maryland statutory status; the All Copays Count Coalition tracks pending state legislation.
Maryland does not currently have a broad statutory any willing pharmacy (AWP) requirement. PBMs operating in Maryland commercial markets may exclude pharmacies from preferred-pharmacy networks subject to general antitrust and contract-formation rules. Patients in plans with narrow preferred-pharmacy networks face higher cost-sharing if filling at out-of-network pharmacies. Verify current Maryland statutory status with the Maryland Department of Insurance; AWP legislation has been periodically debated in many state legislatures.
PBM regulation sets the rules; pharmacy-level discount strategy decides the actual price you pay. See our sister site RxGrab's Maryland generic substitution + Medicaid + SPAP reference for the consumer-side of the question.
Find patient assistance options for your medication with our Assistance Finder, check for drug interactions with the Interaction Checker, or look up your plan's formulary with the Formulary Checker. All tools work nationwide.
Yes. Maryland requires PBMs to obtain state licensure or registration before operating in the state. Following Rutledge v PCMA (2020), state PBM regulation that does not directly conflict with ERISA preemption is permissible, and Maryland is among the majority of states that have enacted formal licensure requirements. See the PBM licensure section above for specific authority and statutory framework.
Yes. Pharmacist gag clauses are prohibited under both federal law (Patient Right to Know Drug Prices Act, 2018) and Maryland's parallel statute, so pharmacists may disclose cash-pay or competitor pricing without violating their PBM contract. Always ask: "What's the cash price?" before running a prescription through insurance, it's sometimes lower than the insurance copay, especially for cheap generics.
No. Maryland has not enacted a copay accumulator prohibition. Health plans operating in Maryland may still use accumulator or maximizer programs that don't credit manufacturer copay assistance toward your deductible. If you depend on a manufacturer card for a specialty medication, you may face full deductible exposure once the card is exhausted. The All Copays Count Coalition tracks state legislative progress.
Subject to your specific health plan's pharmacy network. If your plan uses a "preferred pharmacy network," you generally pay less at preferred pharmacies and more (or sometimes nothing covered) at non-preferred ones. Maryland does not have a broad any-willing-pharmacy statute, so PBMs may exclude pharmacies from preferred networks subject to general antitrust rules. Always confirm your specific medication's network status before filling.